Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (L39373) - R1 - Effective August 6, 2023 Oct 16, 2025
MolDX: Pharmacogenomics Testing (L38335) - R4 - Effective October 2, 2025 Oct 16, 2025
Billing and Coding: Lab: Bladder/Urothelial Tumor Markers (A55028) - R10 - Effective October 1, 2025 Oct 16, 2025
MolDX: Melanoma Risk Stratification Molecular Testing (L37750) - R8 - Effective June 26, 2025 Oct 16, 2025
Policy Revision(s) for Local Coverage Determinations and Associated Billing and Coding Articles - Effective October 16, 2025 Oct 16, 2025
Billing and Coding: Routine Foot Care (A57954) - R17 - Effective October 1, 2025 Oct 16, 2025
Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) (L39810) - R2 - Effective April 17, 2025 Oct 09, 2025
MolDX: Pigmented Lesion Assay (L38151) - R2 - Effective June 20, 2024 Oct 09, 2025
MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer (L37897) - R4 - Effective October 14, 2021 Oct 09, 2025
ProMark Risk Score (L36704) - R6 - Effective December 30, 2021 Oct 09, 2025
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (L39923) - R2 - Effective August 17, 2025 Oct 09, 2025
MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39001) - R5 - Effective July 3, 2025 Oct 09, 2025
MolDX: Molecular Diagnostic Tests (MDT) (L35160) - R17 - Effective May 4, 2025 Oct 09, 2025
Policy Revision(s) for Local Coverage Determinations and Associated Billing and Coding Articles - Effective Multiple Dates Oct 02, 2025
Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells (A58183) - R5 - Effective June 2, 2022 Oct 02, 2025
Billing and Coding: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A57329) - R5 - Effective February 24, 2022 Oct 02, 2025
MolDX: Pharmacogenomics Testing (L38335) - R3 - Effective October 2, 2025 Oct 02, 2025
Billing and Coding: MolDX: Pharmacogenomics Testing (A57384) - R17 - Effective July 3, 2025 Oct 02, 2025
Billing and Coding: MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) (A57423) - R5 - Effective November 7, 2024 Oct 02, 2025
Billing and Coding: MolDX: MGMT Promoter Methylation Analysis (A57432) - R3 - Effective October 14, 2021 Oct 02, 2025
Billing and Coding: MolDX: Oncotype DX Breast Cancer Assay (A54480) - R5 - Effective November 1, 2019 Oct 02, 2025
Policy Revision(s) for Multiple Billing and Coding Articles - Effective October 2, 2025 Oct 02, 2025
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55239) - R22 - Effective October 1, 2025 Oct 02, 2025
2025 ICD-10 Billing and Coding Article Updates - Effective October 1, 2025 Oct 02, 2025
Self-Administered Drug Exclusion List (A53032) - R43 - Effective November 15, 2025 Oct 02, 2025
Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting Announcement - Implantation of Anterior Segment Intraocular Nonbiodegradable Drug-eluting System - November 12, 2025, 2 - 4 pm CT Sep 26, 2025
Billing and Coding: MolDX: Pigmented Lesion Assay (A58052) - R3 - Effective December 23, 2021 Sep 25, 2025
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58973) - R10 - Effective July 1, 2025 Sep 25, 2025
Billing and Coding: MolDX: Prometheus IBD sgi Diagnostic Policy (A57516) - R4 - Effective October 20, 2022 Sep 25, 2025
Billing and Coding: Pulmonary Rehabilitation Services (A56152) - R8 - Effective October 1, 2023 Sep 25, 2025
Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML) (A55711) - R7 - Effective June 1, 2023 Sep 25, 2025
Billing and Coding: MolDX: Oncotype DX Colon Cancer (A54484) - R4 - Effective November 1, 2019 Sep 25, 2025
Billing and Coding: Single Chamber and Dual Chamber Permanent Cardiac Pacemakers - Coding and Billing (A54929) - R12 - Effective October 1, 2023 Sep 25, 2025
Proposed LCDs - Published for Review and Comments Sep 25, 2025
Open Public Meeting Announcement Multiple LCDs - October 30, 2025 Sep 25, 2025
Policy Revision(s) for Multiple Billing and Coding Articles - Effective September 25, 2025 Sep 25, 2025
MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (L39923) - R1 - Effective July 3, 2025 Sep 25, 2025
Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (A59868) - R1 - Effective August 17, 2025 Sep 25, 2025
Billing and Coding: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (A59872) - R1 - Effective August 17, 2025 Sep 25, 2025
Self-Administered Drugs - Process to Determine Which Drugs Are Not Usually Self-administered By the Patient (A53893) - R3 - Effective October 1, 2015 Sep 18, 2025
Local Coverage Determination (LCD) Finalized - Effective November 2, 2025 Sep 18, 2025
Micro Invasive Glaucoma Surgery L38299 - R6 - Effective November 17, 2024 Sep 18, 2025
Billing and Coding: Billing Limitations for Pharmacies (A56119) Retirement - Effective September 18, 2025 Sep 18, 2025
Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) Final LCD - Effective October 26, 2025 Sep 11, 2025
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58720) - R29 - Effective October 1, 2025 Sep 11, 2025
Policy Revision(s) for Local Coverage Determinations and Associated Billing and Coding Articles - Effective September 11, 2025 Sep 11, 2025
Billing and Coding: MolDX: Germline testing for use of PARP inhibitors (A55294) - R12 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58679) - R9 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R13 - Effective October 1, 2025 Sep 04, 2025
Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57037) - R7 - Effective October 1, 2025 Aug 28, 2025